Handelsbanken Fonder AB Takes $1.34 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA

Handelsbanken Fonder AB bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 21,000 shares of the company’s stock, valued at approximately $1,343,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in KNSA. Financial Enhancement Group LLC acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $2,007,000. Bank of America Corp DE raised its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after purchasing an additional 506,576 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after purchasing an additional 327,595 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Kiniksa Pharmaceuticals International by 33.3% in the first quarter. California State Teachers Retirement System now owns 41,975 shares of the company’s stock valued at $2,021,000 after purchasing an additional 10,477 shares in the last quarter. Finally, Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after buying an additional 421,347 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Up 0.4%

Kiniksa Pharmaceuticals International stock opened at $79.49 on Wednesday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $32.89 and a 52 week high of $82.94. The company’s 50 day moving average price is $65.64 and its two-hundred day moving average price is $54.24. The stock has a market cap of $6.20 billion, a P/E ratio of 81.95 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.30. The company had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current year.

Analyst Upgrades and Downgrades

KNSA has been the subject of several recent research reports. Canaccord Genuity Group upped their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, August 13th. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and a consensus price target of $87.38.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the transaction, the director owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.